Guidelines on the Use of therapeutic apheresis in clinical practice–Evidence‐Based approach from the Writing Committee of the American Society for Apheresis: The …
L Connelly‐Smith, CR Alquist, NA Aqui… - Journal of clinical …, 2023 - Wiley Online Library
Abstract The American Society for Apheresis (ASFA) Journal of Clinical Apheresis (JCA)
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
Special Issue Writing Committee is charged with reviewing, updating, and categorizing …
[HTML][HTML] Incidence, risk factors, and outcome of immune-mediated neuropathies (IMNs) following haploidentical hematopoietic stem cell transplantation
X Ren, X Liu, Q Huang, Q Wang, Y He, X Zhu… - Biology of Blood and …, 2019 - Elsevier
Immune-mediated neuropathies (IMNs) following hematopoietic stem cell transplantation
have been described recently, which, excluding Guillain-Barré syndrome and chronic …
have been described recently, which, excluding Guillain-Barré syndrome and chronic …
[HTML][HTML] 异基因造血干细胞移植后免疫介导神经病变一例并文献复习
罗成伟， 黄欣， 吴穗晶， 翁建宇， 杜欣 - Chinese Journal of …, 2018 - ncbi.nlm.nih.gov
异基因造血干细胞移植(allo-HSCT) 仍是目前治疗血液肿瘤的有效手段, 移植后神经系统并发症
的发生率为14%~ 42%[1]. 移植后1 个月内发生的神经系统并发症往往与药物, 感染 …
的发生率为14%~ 42%[1]. 移植后1 个月内发生的神经系统并发症往往与药物, 感染 …
[PDF][PDF] Cancer therapy and neuromuscular complications: a mini review
Neuromuscular complications can be caused by all types of interventions, various
mechanisms and occur and as acute, chronic or late effects. The most frequent causes of …
mechanisms and occur and as acute, chronic or late effects. The most frequent causes of …
Immune-mediated neuropathy after allogeneic hematopoietic stem cell transplantation: one case report and literature review
CW Luo, X Huang, SJ Wu, JY Weng… - Zhonghua xue ye xue za …, 2018 - europepmc.org
异基因造血干细胞移植 (allo-HSCT) 仍是目前治疗血液肿瘤的有效手段, 移植后神经系统并发症
的发生率为 14%~ 42%[1]. 移植后 1 个月内发生的神经系统并发症往往与药物, 感染 …
的发生率为 14%~ 42%[1]. 移植后 1 个月内发生的神经系统并发症往往与药物, 感染 …